初产妇早产胎膜早破的早期鉴别

文献信息

中文摘要

引言： 自2022年起，生物制剂治疗慢性鼻窦炎伴鼻息肉（CRSwNP）已在丹麦获批。全球气道指导小组将胸部X线（CXR）作为治疗前筛查，用于识别肺部疾病并监测不良反应。本研究评估在CRSwNP患者开始生物制剂治疗前常规CXR筛查的效用。
方法： 基线数据（包括胸部X线）在全国性Global Airways登记处前瞻性收集（经丹麦研究伦理委员会批准，批准号：H-21020685），并于2025年5月进行分析。
结果： 共识别并纳入511例患者（男性335例，女性176例；平均年龄46.5 ± 14.6岁）；247例患者开始生物制剂治疗。在治疗组中，136例（55%）CXR正常，12例（5%）有异常发现。在未接受生物制剂治疗的264例患者中，143例（54%）CXR正常，10例（4%）显示异常发现。
结论： 在CRSwNP患者生物制剂治疗前进行常规基线CXR筛查发现的异常结果很少。因此，常规CXR可能提供的临床获益有限。
资助： Global Airways数据库由GlaxoSmithKline、Sanofi和Astra Zeneca资助。任何制药公司均无权访问数据。
试验注册： 不相关。

英文摘要

INTRODUCTION: Biologic therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) have been approved in Denmark since 2022. Chest X-ray (CXR) was implemented by the Global Airways Steering Group as pre-treatment screening to identify pulmonary conditions and monitor adverse effects. This study evaluates the utility of routine CXR screening before initiating biological therapy in patients with CRSwNP.
METHODS: Baseline data, including chest X-ray, were collected prospectively in the nationwide Global Airways Registry (approved by the Danish Research Ethics Committee R. no.: H-21020685) and analysed in May 2025.
RESULTS: A total of 511 patients (335 males, 176 females; mean age 46.5 ± 14.6) years were identified and included in this study; 247 patients were initiated on biologic therapy. In the treatment group, 136 (55%) had normal CXRs, and 12 (5%) had abnormal findings. Among the 264 patients who did not receive biologic treatment, 143 (54%) had normal CXRs and ten (4%) demonstrated abnormal findings.
CONCLUSIONS: Routine baseline CXR screening before biologic therapy in patients with CRSwNP identified few abnormal findings. Accordingly, routine CXR is likely to offer limited clinical benefit.
FUNDING: The Global Airways database is funded by GlaxoSmithKline, Sanofi and Astra Zeneca. None of the pharmaceutical companies has access to data.
TRIAL REGISTRATION: Not relevant.